-
Jan 7, 2025 | 
nature.com | Praful Ravi |Daniel E. Spratt
AbstractPatients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3; “high-risk”) have better outcomes than those with 2–3 factors and/or cN1 disease (“very high risk”). We evaluated whether this risk stratification could determine benefit from ltADT versus short-term (stADT).
-
Nov 15, 2024 | 
urotoday.com | Daniel E. Spratt
Read the Full Video TranscriptDaniel Spratt: Now we're talking post-operative; the guy chose to have surgery and he's had a biochemical recurrence. So should we add systemic therapy? What type and for how long? So as you've heard briefly, four of the primary phase III randomized trials have been discussing at least using hormone therapy.
-
Nov 15, 2024 | 
urotoday.com | Daniel E. Spratt
Read the Full Video TranscriptDaniel Spratt: So I'm hyper-simplifying the NCCN guidelines for what I'm going to talk about today—decisions of when we add short-term hormone therapy, long-term hormone therapy, and now a consideration of Abiraterone. And the basis—what is the primary biomarker in NCCN risk group? So it's a Gleason score, and this is the Gleason system taken from the work from about 60 years ago based upon seven PCSM events.
-
Oct 16, 2024 | 03465-5/fulltext?rss=yes&sz=64)
redjournal.org | Mark Reardon |Translational Oncogenomics |Daniel E. Spratt |Alex Hakansson
Keywordsprostate cancerbiochemical recurrencehypoxiaandrogen deprivation therapyIntroductionProstate cancer (PCa) is diagnosed in 1.4 million men globally each year and causes 375,000 deaths, making PCa the second-most common cancer and fifth-most common cause of cancer death in men [1]. Patients are stratified by clinical parameters such as blood prostate-specific antigen (PSA) levels, tumour T-stage and histopathological Gleason grade group into low, intermediate, and high-risk PCa [2].
-
Sep 23, 2024 | 03323-6/fulltext&sz=64)
redjournal.org | Daniel E. Spratt |South San Francisco |Jeff M. Michalski
⁎Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio †Veracyte, Inc, South San Francisco, California ‡Department of Radiation Oncology, Washington University, St. Louis, Missouri §Princess Margaret Cancer Centre, Cancer Clinical Research Unit, Toronto, Ontario, Canada ‖Department of Pathology, UCSF Medical Center-Mount Zion, San Francisco, California ¶Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston,...
-
May 28, 2024 | 
urotoday.com | Daniel E. Spratt
Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Dan Spratt, who is joining me from Case Western Reserve University and the Seidman Cancer Center, as well as joining me recently in Lugano for APCCC 2024. Thank you so much for being here with me today, Dan. Daniel Spratt: Thanks so much for having me. Alicia Morgans: Wonderful.
-
May 22, 2024 | 02375-3/abstract?rss=yes&sz=64)
europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more
Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.
-
Mar 15, 2024 | 
futuremedicine.com | Daniel E. Spratt |Tanya B. Dorff |Rana R. McKay |Benjamin H. Lowentritt
Prostate cancer is the most prevalent cancer in men and the second leading cause of cancer death in men in the USA. In 2023, American Cancer Society estimated 288,300 new prostate cancer cases (29% of male cancer cases), with 34,700 estimated deaths (11% of male cancer death) [1]. Prostate cancer incidence increases with increasing age, with the average age at the diagnosis time being 66 years.
-
Nov 15, 2023 | 
urotoday.com | Daniel E. Spratt
Read the Full Video TranscriptJason Hafron: I would like to introduce the speaker for our next session, What's New in Radiation Oncology, Dr. Dan Spratt. Dr. Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University. He has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal, JAMA Lancet, JAMA Oncology, JCO.
-
Nov 15, 2023 | 
urotoday.com | Daniel E. Spratt
Read the Full Video TranscriptDaniel Spratt: I did mention hormone therapy, a lot of guys, especially as we get into the higher grades, we give hormone therapy to. So what's coming very soon in this talk, there's a ton of work being done with this 22-gene classifier that I won't be talking about today.
